8ª Edição – Especial Simpósio

Genomic tests are increasingly common in oncology

per: Grupo Oncoclínicas
Genomic tests are increasingly common in oncology

Scientific commission

Bruno Ferrari
Bruno Ferrari
Carlos Gil
Carlos Gil
Paula Ugalde
Paula Ugalde
Sérgio Azevedo
Sérgio Azevedo

Contributors

Betina Vollbrecht
Betina Vollbrecht
Max Mano
Max Mano

Molecular tests to define the type of breast cancer have changed the prognosis for the disease. In metastatic cancer, the largest bet is on the use of genomic tests as a tool to define the best clinical management protocol. These were some of the topics discussed by the oncologists who participated in the Breast Cancer panel at the 8th International Symposium promoted by the Oncoclínicas Group, which was held virtually this year.\

Coordinator of the clinical panels of the breast cancer module of the symposium, oncologist Max Senna Mano drew attention to the debates related to molecular tests. “Breast tumors continue to be classified by conventional histopathology and immunohistochemistry approaches, but more complex molecular tests, such as genomic sequencing, are starting to change this scenario, in a process that should accelerate dramatically in the coming years”, he evaluated, who is the head of the breast cancer team of the Oncoclínicas Group.

The event also featured a live surgery. Betina Vollbrecht, a breast specialist at Grupo Oncoclínicas, in Rio Grande do Sul, participated in the procedure. She highlights, in the surgical field, the issue of margins: “We demonstrated how, after removing the tumor, to collect samples from all margins – superior, inferior, lateral, superficial and deep margins – for evaluation”.

Visit our website and read the full report.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L